CPI Accelerates Gene Therapy Development with Robust Adeno-Associated Virus Purification System in Partnership with Cobra Biologics and GE Healthcare
The new process will remove a significant bottleneck in the development of gene therapies, and enable these innovative products to be brought to market more quickly.
CPI has announced the success of its CRD IUK project to develop a scalable, cost-effective purification process for adeno-associated viruses (AAVs), in partnership with Cobra Biologics and GE Healthcare Life Sciences. The new process will remove a significant bottleneck in the development of gene therapies, and enable these innovative products to be brought to market more quickly.